Breathing new life into an old target: pulmonary disease drugs for Parkinson's disease therapy.
Publication
, Journal Article
Abdelmotilib, H; West, AB
Published in: Genome Med
October 19, 2017
Increases in α-synuclein protein expression are suspected to increase the risk of the development of Parkinson's disease (PD). A recent study has demonstrated that β2-adrenergic receptor (β2AR) agonists decrease histone acetylation in the α-synuclein gene and suppress transcription. Coupled with the anti-inflammatory effects that are associated with β2AR activation, this two-pronged attack holds promise for PD treatment and the development of new therapeutic approaches for this disease.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Genome Med
DOI
EISSN
1756-994X
Publication Date
October 19, 2017
Volume
9
Issue
1
Start / End Page
88
Location
England
Related Subject Headings
- alpha-Synuclein
- Parkinson Disease
- Humans
- Drug Delivery Systems
- Antiparkinson Agents
- Adrenergic beta-2 Receptor Agonists
- 3105 Genetics
- 1103 Clinical Sciences
- 0604 Genetics
Citation
APA
Chicago
ICMJE
MLA
NLM
Abdelmotilib, H., & West, A. B. (2017). Breathing new life into an old target: pulmonary disease drugs for Parkinson's disease therapy. Genome Med, 9(1), 88. https://doi.org/10.1186/s13073-017-0483-4
Abdelmotilib, Hisham, and Andrew B. West. “Breathing new life into an old target: pulmonary disease drugs for Parkinson's disease therapy.” Genome Med 9, no. 1 (October 19, 2017): 88. https://doi.org/10.1186/s13073-017-0483-4.
Abdelmotilib H, West AB. Breathing new life into an old target: pulmonary disease drugs for Parkinson's disease therapy. Genome Med. 2017 Oct 19;9(1):88.
Abdelmotilib, Hisham, and Andrew B. West. “Breathing new life into an old target: pulmonary disease drugs for Parkinson's disease therapy.” Genome Med, vol. 9, no. 1, Oct. 2017, p. 88. Pubmed, doi:10.1186/s13073-017-0483-4.
Abdelmotilib H, West AB. Breathing new life into an old target: pulmonary disease drugs for Parkinson's disease therapy. Genome Med. 2017 Oct 19;9(1):88.
Published In
Genome Med
DOI
EISSN
1756-994X
Publication Date
October 19, 2017
Volume
9
Issue
1
Start / End Page
88
Location
England
Related Subject Headings
- alpha-Synuclein
- Parkinson Disease
- Humans
- Drug Delivery Systems
- Antiparkinson Agents
- Adrenergic beta-2 Receptor Agonists
- 3105 Genetics
- 1103 Clinical Sciences
- 0604 Genetics